Ascendis Health's journey from near-bankruptcy to profitability showcases how strategic leadership and financial discipline ...

Ascendis Pharma A/S Price Performance Shares of ASND stock opened at $150.31 on Thursday. The stock’s fifty day moving average price is $137.77 and its 200 day moving average price is $134.52 ...

Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...

Despite the day’s gains, Ascendis shares remain down over 10% in the past year and trade about 54% below the average analyst target of $193.49, according to Koyfin data. The company’s stock ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...

Ascendis Pharma ended 2024 with strong momentum, driven by SKYTROFA’s revenue growth and YORVIPATH’s U.S. launch. With €665 million in cash and multiple product expansions planned for 2025 ...

“Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong revenue growth in 2025 and beyond,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive ...

Ascendis Pharma A/S (NASDAQ:ASND) defied analyst predictions to release its annual results, which were ahead of market expectations. The overall earnings picture was okay, with revenues of €364m ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...

On Wednesday, Ascendis Pharma (NASDAQ:ASND) reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros. Total revenue for the fourth quarter of 2024 was 173.9 million ...

Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a $9.07 billion market capitalization focused on developing transformative therapies for rare endocrine disorders, has been ...

Ascendis Pharma posted a Q4 EPS loss of €0.64, beating estimates of a €1.07 loss, with revenue of €173.9M surpassing the €111.18M consensus. Yorvipath saw 908 U.S. prescriptions by Feb. 7 ...